I know the price is frustrating, but I cannot believe Marcum is doing our audit and other people continue to provide services behind the scenes to the parent ambs and the subs if the AP was not being settled as outlined, with equivalent shares at a small discount. Those other companies are facing the same thing as the toxics. Don't get paid at all, or participate in upside. I will be frustrated and panicked if we're deep into September with nothing new. Cutanogen and Elto are clearly advancing, the only question for us if the deals get signed before the dilution begins in 2019. I also think and hope GC takes most of his shares, Chan, and Spence's shares into a new class of preferred. Upping the A/S is a canary to watch.